Satya is developing transformative drugs for cancer, inflammation, and metabolic disorders. We deploy an integrated approach, combining traditional drug discovery methods with artificial intelligence (AI)
Traditional Drug Discovery Enhanced by AI
Satya leverages deep expertise in traditional drug discovery, which involves identifying and validating biological targets, followed by the design and optimization of small molecule drugs. This traditional process is enhanced by thoughtfully integrating AI tools, including virtual screening, quantitative structure-activity relationship (QSAR) modeling, and de novo drug design, all of which Satya employs to gain profound insights into target biology and drug design.
The company's teams access extensive scientific literature and curate public databases, ensuring a robust foundation of knowledge.
Focus on Critical Biological Pathways
Satya's strategy centers on selecting biological targets critical to the cell cycle, DNA-damage repair, and metabolic pathways, aiming to modulate them to address underlying diseases while minimizing effects on normal cellular processes.
Our focus on DDR is particularly notable, with a pioneering approach to targeting RAD51:BRCA2 interactions, which we identified as a tumor-agnostic mechanism for RAD51-high cancers. This innovation shows leads to exploring its potential for addressing cancers with high replication stress, as we have identified high RAD51 foci as both a biomarker and driver of resistance
Balancing Efficacy and Safety
A core principle in Satya's approach is to modulate biological targets in a way that maximizes therapeutic benefit while minimizing side effects. This is achieved through careful target selection and optimization, ensuring drugs affect disease-causing pathways without unduly disrupting normal cellular functions.
Our exploration of metabolic pathways is focused on treatments for diabetes and obesity, while maintaining a favorable safety profile and overcoming challenges in current approaches to obesity treatment, such as mitigating GI toxicities and preservation of lean muscle mass